Janus Henderson Group
CBIO

Janus Henderson Group’s Crescent Biopharma CBIO Stock Holding History

Janus Henderson Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-11,007
Closed -$13.1M – 1414
2019
Q2 		$13.1M Sell
11,007
-276
-2% -$330K 0.01% 892
2019
Q1 		$14.1M Sell
11,283
-689
-6% -$789K 0.01% 851
2018
Q4 		$11.3M Buy
11,972
+277
+2% +$333K 0.01% 880
2018
Q3 		$16.8M Sell
11,695
-150
-1% -$227K 0.01% 846
2018
Q2 		$19.1M Sell
11,845
-225
-2% -$387K 0.01% 812
2018
Q1 		$19.6M Buy
12,070
+2,292
+23% +$4.77M 0.01% 797
2017
Q4 		$16.4M Buy
9,778
+4,903
+101% +$6.48M 0.01% 791
2017
Q3 		$6.82M Sell
4,875
-141
-3% -$166K ﹤0.01% 924
2017
Q2 		$5.6M Buy
+5,016
New +$4.14M ﹤0.01% 969

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Janus Henderson Group's CBIO Position: Q3 2019 in Review

Janus Henderson Group sold out of Crescent Biopharma (CBIO) in Q3 2019, closing a stake of 11,007 shares — an estimated $13.1M sold.

Janus Henderson Group first reported a position in CBIO in Q2 2017 and held it in 9 quarters. The position peaked at $19.6M in Q1 2018. 75 funds tracked by Wall St. Rank hold CBIO as of Q3 2019.

  • Janus Henderson Group reported no remaining Crescent Biopharma position as of Q3 2019 after selling out during the quarter.
  • Janus Henderson Group sold 11,007 Crescent Biopharma shares in Q3 2019, an estimated $13.1M.
  • Janus Henderson Group first reported a position in Crescent Biopharma in Q2 2017 and held it in 9 quarters.
  • Janus Henderson Group's Crescent Biopharma position peaked at $19.6M in Q1 2018.
  • 75 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2019.

Based on Janus Henderson Group's 13F filing for Q3 2019, filed 14 Nov 2019.